COMPLETE KIT INCLUDEDbacteriostatic water, syringes, protocol and guide with every order

Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•
BioPeptideX logoBioPeptideX
Back

Research guide · Metabolic Support

Tesamorelin — research protocol

Compound studied for its role in stimulating natural growth hormone release. Lyophilized powder for stability.

Evidence boundary

This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.

Catalog presentations

5mg10mg20mg30mg

Concentration table

Mathematical reference only; this is not a dosing recommendation.

Resulting concentration2.50 mg/mL
On a U-100 syringe · 1 unit contains0.025 mg

Research areas

  • GHRH analog
  • Lyophilized for extended stability
  • 99% HPLC verified purity

Most-cited research protocols

Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.

Tesamorelin is an FDA-approved GHRH peptide that signals the pituitary gland to release more natural growth hormone. It is sold as Egrifta SV and Egrifta WR for HIV-related belly fat (lipodystrophy), and as research-grade vials for off-label study.

DoseFrequencyDurationRoute
Research Vials2 mgDailyDay 1 onwardSubcutaneous in the abdomen
Egrifta SV1.4 mgDailyDay 1 onwardSubcutaneous in the abdomen
Egrifta WR1.28 mgDailyDay 1 onwardSubcutaneous in the abdomen

Cycle: Standard 26 weeks, Extended 52 weeks, or Long-term (NAFLD context) 12 months. Sustained therapy is generally needed to keep results as effects trend back toward baseline after stopping.

Benefits and research observations: IGF-1 levels and GH output rise by Week 2, early visceral fat decrease begins by Week 13, and primary endpoint (VAT reduction) is observed at Week 26. Maintain VAT effects with continued therapy.

Handling and storage

Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.

Warnings

Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.

Published sources

  1. 1.Falutz J, et al. NEJM, 2007.
  2. 2.Stanley TL, et al. JCEM, 2011.